Literature DB >> 1411529

Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors.

R M Nitsch1, B E Slack, R J Wurtman, J H Growdon.   

Abstract

Altered processing of the amyloid precursor protein (APP) is a central event in the formation of amyloid deposits in the brains of individuals with Alzheimer's disease. To investigate whether cellular APP processing is controlled by cell-surface neurotransmitter receptors, human embryonic kidney (293) cell lines were transfected with the genes for human brain muscarinic acetylcholine receptors. Stimulation of m1 and m3 receptor subtypes with carbachol increased the basal release of APP derivatives within minutes of treatment, indicating that preexisting APP is released in response to receptor activation. Receptor-activated APP release was blocked by staurosporine, suggesting that protein kinases mediate neurotransmitter receptor-controlled APP processing.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1411529     DOI: 10.1126/science.1411529

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  186 in total

1.  Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation.

Authors:  L Lin; B Georgievska; A Mattsson; O Isacson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

2.  The M1 muscarinic agonist CI-1017 facilitates trace eyeblink conditioning in aging rabbits and increases the excitability of CA1 pyramidal neurons.

Authors:  C Weiss; A R Preston; M M Oh; R D Schwarz; D Welty; J F Disterhoft
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

3.  The amyloid precursor protein interacts with Go heterotrimeric protein within a cell compartment specialized in signal transduction.

Authors:  E Brouillet; A Trembleau; D Galanaud; M Volovitch; C Bouillot; C Valenza; A Prochiantz; B Allinquant
Journal:  J Neurosci       Date:  1999-03-01       Impact factor: 6.167

Review 4.  Pharmacogenetic features of cathepsin B inhibitors that improve memory deficit and reduce beta-amyloid related to Alzheimer's disease.

Authors:  Vivian Hook; Gregory Hook; Mark Kindy
Journal:  Biol Chem       Date:  2010-08       Impact factor: 3.915

5.  The utility of muscarinic agonists in the treatment of Alzheimer's disease.

Authors:  William S Messer
Journal:  J Mol Neurosci       Date:  2002 Aug-Oct       Impact factor: 3.444

Review 6.  Axonal transport of APP and the spatial regulation of APP cleavage and function in neuronal cells.

Authors:  Silke Brunholz; Sangram Sisodia; Alfredo Lorenzo; Carole Deyts; Stefan Kins; Gerardo Morfini
Journal:  Exp Brain Res       Date:  2011-09-30       Impact factor: 1.972

Review 7.  Alzheimer's disease: strategies for disease modification.

Authors:  Martin Citron
Journal:  Nat Rev Drug Discov       Date:  2010-05       Impact factor: 84.694

8.  Lysophosphatidic acid induces increased BACE1 expression and Aβ formation.

Authors:  Jing Shi; Yunzhou Dong; Mei-Zhen Cui; Xuemin Xu
Journal:  Biochim Biophys Acta       Date:  2012-10-02

9.  beta-Amyloid precursor protein isoforms show correlations with neurones but not with glia of demented subjects.

Authors:  A W Procter; P T Francis; C Holmes; M T Webster; M Qume; G C Stratmann; R Doshi; D M Mann; P J Harrison; R C Pearson
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

10.  BMP9 ameliorates amyloidosis and the cholinergic defect in a mouse model of Alzheimer's disease.

Authors:  Rebecca M Burke; Timothy A Norman; Tarik F Haydar; Barbara E Slack; Susan E Leeman; Jan Krzysztof Blusztajn; Tiffany J Mellott
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.